Regenera receives ethics approval for second clinical trial
Wednesday, 20 October, 2004
Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.
Visagen is a preservative free formulation of the steroid triamcinolone acetonide.
The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
